Treatment for asymptomatic vaginal candidiasis to reduce preterm birth: a systematic review
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250521Keywords:
Asymptomatic vaginal candidiasis, Preterm birth, Treatment, Pregnancy complications, Antifungal therapy, Maternal health, ReviewAbstract
Vaginal candidiasis, a prevalent fungal infection in women caused by the overgrowth of Candida species, primarily Candida albicans, often triggers a hyperimmune response. While it is rarely life-threatening, it can be uncomfortable, posing risks to both pregnant mothers and their unborn children, thus affecting quality of life. This systematic review aimed to determine whether treating asymptomatic vaginal candidiasis during pregnancy reduces the incidence of preterm birth. Literature search was conducted across four electronic databases finds randomised controlled trials (RCTs) comparing the treatment of vaginal candidiasis (clotrimazole) with usual care (no-treatment). The search was updated in August 2024, with no language restrictions. Participants were pregnant women between 12 and 20 weeks of gestation. The primary outcome measured was the rate of preterm birth, while secondary outcomes included adverse pregnancy events such as premature rupture of membranes, perinatal death, low birth weight, and stillbirth. Data analysis utilized review manager (RevMan) software. Three RCTs involving 3,868 pregnant women were included, with 1,942 in the clotrimazole group and 1,926 in the usual care group. The primary outcome revealed spontaneous preterm birth rates of 2% in the treatment group compared to 6.3% in the usual care group. Meta-analysis indicated a statistically significant effect favouring treatment, with a pooled effect size of -0.05 (95% CI -0.09, -0.01). Treating asymptomatic candidiasis in early pregnancy appears to reduce preterm birth risk. However, results should be interpreted cautiously due to the limited number of studies. Further well-designed trials are needed to optimise treatment strategies and assess their impact on neonatal outcomes.
Metrics
References
Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal candidiasis: A current understanding and burning questions. J Fungi (Basel). 2020;6(1):27. DOI: https://doi.org/10.3390/jof6010027
Donders G, Sziller IO, Paavonen J, Phillip H, Francesco S, Jean MB, et al. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and european expert panel opinion. Front Cell Infect Microbiol. 2022;12:934353. DOI: https://doi.org/10.3389/fcimb.2022.934353
Dong Z, Fan C, Hou W, Can R, Xinyan W, Yuru F, et al. Vaginal exposure to Candida albicans during early gestation results in adverse pregnancy outcomes via inhibiting placental development. Front Microbiol. 2022;12:816161. DOI: https://doi.org/10.3389/fmicb.2021.816161
Anh DN, Hung DN, Tien TV, Vu ND, Vu TS, Nguyen VL, et al. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam. BMC Infect Dis. 2021;21(1):523-7. DOI: https://doi.org/10.1186/s12879-021-06192-7
Osman Mohamed A, Suliman Mohamed M, Hussain Mallhi T, et al. Prevalence of vulvovaginal candidiasis among pregnant women in Africa: A systematic review and meta-analysis. J Infect Dev Ctries. 2022;16(8):1243-51. DOI: https://doi.org/10.3855/jidc.15536
Silasi M, Cardenas I, Kwon J, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73(3):199-213. DOI: https://doi.org/10.1111/aji.12355
Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev. 2001;(4):CD000225. DOI: https://doi.org/10.1002/14651858.CD000225
Zaman R, Ullah I, Adeeb H, Arif A. Azoles resistance of Candida species causing vulvo-vaginitis in reproductive age women at a tertiary care setting. Pak J Med Sci. 2022;38(8):2239-45. DOI: https://doi.org/10.12669/pjms.38.8.5984
Pasternak B, Wintzell V, Furu K, Engeland A, Neovius M, Stephansson O. Oral fluconazole in pregnancy and risk of stillbirth and neonatal death. JAMA. 2018;319(22):2333-5. DOI: https://doi.org/10.1001/jama.2018.6237
Bérard A, Sheehy O, Zhao J, Jessica G, Sasha B, Cristiano SM, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019;191(7):E179-87. DOI: https://doi.org/10.1503/cmaj.180963
Zhu Y, Bateman BT, Gray KJ, Sonia HD, Helen M, Loreen S, et al. Oral fluconazole use in the first trimester and risk of congenital malformations: Population based cohort study. BMJ. 2020;369:m1494. DOI: https://doi.org/10.1136/bmj.m1494
Denison HJ, Worswick J, Bond CM, Jeremy MG, Alain M, Shakila GR, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2020;8(8):CD002845. DOI: https://doi.org/10.1002/14651858.CD002845.pub3
Almangour TA, Kaye KS, Alessa M, Khalid E, Fadilah SA, Aynaa A, et al. Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials. Saudi Pharm J. 2021;29(4):315-23. DOI: https://doi.org/10.1016/j.jsps.2021.03.003
Patel MA, Aliporewala VM, Patel DA. Common antifungal drugs in pregnancy: Risks and precautions. J Obstet Gynaecol India. 2021;71(6):577-82. DOI: https://doi.org/10.1007/s13224-021-01586-8
Kinney MV, Lawn JE, Howson CP, Belizan J. 15 million preterm births annually: What has changed this year? Reprod Health. 2012;9:28. DOI: https://doi.org/10.1186/1742-4755-9-28
Vogel JP, Oladapo OT, Manu A, Gülmezoglu AM, Bahl R. New WHO recommendations to improve the outcomes of preterm birth. The Lancet Global Health. 2015;3(10):e589-90. DOI: https://doi.org/10.1016/S2214-109X(15)00183-7
Sule-Odu AO, Akadri AA, Oluwole AA, Olubunmi AO, Babatunde AA, Adeniyi KA, et al. Vaginal Candida infection in pregnancy and its implications for fetal well-being. Afr J Reprod Health. 2020;24(3):33-40.
Schuster HJ, de Jonghe BA, Limpens J, Budding AE, Painter RC. Asymptomatic vaginal Candida colonization and adverse pregnancy outcomes including preterm birth: A systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(3):100163. DOI: https://doi.org/10.1016/j.ajogmf.2020.100163
Page MJ, McKenzie JE, Bossuyt PM, Isabelle B, Tammy CH, Cynthia DM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: https://doi.org/10.1136/bmj.n71
Higgins JP. Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration and John Wiley and Sons Ltd. 2008. DOI: https://doi.org/10.1002/9780470712184
Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004;329(7462):371. DOI: https://doi.org/10.1136/bmj.38169.519653.EB
Vatsayan A, Byrnes O, Dalal R, Davis G, Hyett J, McGee T. Candida in pregnancy study (CIPS). Aust J Paediatr Child Heal. 2020;1:3-153.
Roberts CL, Rickard K, Kotsiou G, Morris JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: An open-label pilot randomized controlled trial. BMC Pregnancy Childbirth. 2011;11:18. DOI: https://doi.org/10.1186/1471-2393-11-18
Disha T, Haque F. Prevalence and risk factors of vulvovaginal candidosis during pregnancy: A review. Infect Dis Obstet Gynecol. 2022;2022:6195712. DOI: https://doi.org/10.1155/2022/6195712
Farr A, Effendy I, Frey Tirri B, Herbert H, Peter M, Ljubomir P, et al. Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses. 2021;64(6):583-602. DOI: https://doi.org/10.1111/myc.13248
Khan M, Ahmed J, Gul A, Ikram A, Lalani FK. Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infect Drug Resist. 2018;11:447-56. DOI: https://doi.org/10.2147/IDR.S153116
Gigi RMS, Buitrago-Garcia D, Taghavi K, Cara-Mia D, Janneke HHMW, Remco PHP, et al. Vulvovaginal yeast infections during pregnancy and perinatal outcomes: Systematic review and meta-analysis. BMC Women’s Health. 2023;23(1):116-7. DOI: https://doi.org/10.1186/s12905-023-02258-7
Association of chlamydia trachomatis and mycoplasma hominis with intrauterine growth retardation and preterm delivery. the John Hopkins study of cervicitis and adverse pregnancy outcome. Am J Epidemiol. 1989;129(6):1247-57. DOI: https://doi.org/10.1093/oxfordjournals.aje.a115244
McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W, et al. Prevention of premature birth by screening and treatment for common genital tract infections: Results of a prospective controlled evaluation. Am J Obstet Gynecol. 1995;173(1):157-67. DOI: https://doi.org/10.1016/0002-9378(95)90184-1
Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. vaginal infections and prematurity study group. Am J Obstet Gynecol. 1998;178(2):374-80. DOI: https://doi.org/10.1016/S0002-9378(98)80028-8
Lamont RF. Advances in the prevention of infection-related preterm birth. Front Immunol. 2015;6:566. DOI: https://doi.org/10.3389/fimmu.2015.00566
Liao J, Shenhav L, Urban JA, Myrna S, Bin Z, Gregory AB, et al. Microdiversity of the vaginal microbiome is associated with preterm birth. Nat Commun. 2023;14(1):4997-7. DOI: https://doi.org/10.1038/s41467-023-40719-7
Liu L, Chen Y, Chen J, Han-Jie X, Hui-Ying Z, Zhong C, et al. Integrated metagenomics and metabolomics analysis of third-trimester pregnant women with premature membrane rupture: A pilot study. Ann Transl Med. 2021;9(23):1724-5539. DOI: https://doi.org/10.21037/atm-21-5539
Jeanmonod R, Chippa V, Jeanmonod D. Vaginal candidiasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC. 2024.
Netea MG, Joosten LAB, van der Meer JWM, Kullberg B, van de Veerdonk FL. Immune defence against Candida fungal infections. Nat Rev Immunol. 2015;15(10):630-42. DOI: https://doi.org/10.1038/nri3897
Downloads
Published
How to Cite
Issue
Section
